CBD vs THC: What are the differences

THC vs CBD

Two of the most common cannabinoids found within the plant are THC (Tetrahydrocannabinol) and CBD (Cannabidiol)

Therefore the euphoria commonly associated with cannabis family is caused by the THC compound, which is psychoactive and creates a “high” effect.

THC cannabinoids produce the effects associated with cannabis by binding to the Endocannabinoid System CB1 cannabinoid receptors in the brain. Recent evidence shows that the CBD compound counteracts cognitive impairment associated with the use of cannabis. But what is CBD and how does it work?

Cannabidiol has little affinity for CB1 and CB2 receptors of the body’s Endocannabinoid System but acts as an indirect antagonist of cannabinoid agonists. There is no way to become intoxicated from its use.

In recent times the US government has sponsored scientific and clinical research which underscores CBD’s potential as a treatment for a wide range of conditions.

Known as phytocannabinoids, these compounds interact with CB1 and CB2 receptors found in the endocannabinoid system present in all mammalian species.

At the most fundamental level, THC and CBD are different because of their differing physiological effects.

As the legal use of marijuana and other cannabis products grows, consumers are becoming more curious about their options.

CBD  is sold in several forms such as gels, gummies, oils, supplements, extracts, and more.

THC is the main psychoactive compound in marijuana. It’s uses includes smoking marijuana. It’s also available in oils, edibles, tinctures, capsules, and more.

Both compounds interact with your body’s endocannabinoid system but they have very different effects.

THC and Cancer

Mounting evidence shows ‘cannabinoids’ in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects.

Cristina Sanchez, a young biologist at Complutense University in Madrid, was studying cell metabolism when she noticed something peculiar. She had been screening brain cancer cells because they grow faster than normal cell lines and thus are useful for research purposes. But the cancer cells died each time they were exposed to tetrahydrocannabinol (THC), the principal psychoactive ingredient of marijuana.

Instead of gaining insight into how cells function, Sanchez had stumbled upon the anti-cancer properties of THC. In 1998, she reported in a European biochemistry journal that THC “induces apoptosis [cell death] in C6 glioma cells,” an aggressive form of brain cancer.

Subsequent peer-reviewed studies in several countries would show that THC and other marijuana-derived compounds, known as “cannabinoids,” are effective not only for cancer-symptom management (nausea, pain, loss of appetite, fatigue), they also confer a direct antitumoral effect.

A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. Guzman administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma, who had failed to respond to standard brain-cancer therapies. The results were published in 2006 in the British Journal of PharmacologyTHC treatment was associated with significantly reduced tumor cell proliferation in every test subject.

Around the same time, Harvard University scientists reported that THC slows tumor growth in common lung cancer and “significantly reduces the ability of the cancer to spread.” What’s more, like a heat-seeking missile, THC selectively targets and destroys tumor cells while leaving healthy cells unscathed. Conventional chemotherapy drugs, by contrast, are highly toxic; they indiscriminately damage the brain and body.

There is mounting evidence, according to a report in Mini-Reviews in Medicinal Chemistry, that cannabinoids “represent a new class of anticancer drugs that retard cancer growth, inhibit angiogenesis [the formation of new blood cells that feed a tumor] and the metastatic spreading of cancer cells.”

Dr. Sean McAllister, a scientist at the Pacific Medical Center in San Francisco, has been studying cannabinoid compounds for 10 years in a quest to develop new therapeutic interventions for various cancers.

Backed by grants from the National Institute of Health (and with a license from the DEA), McAllister discovered that cannabidiol (CBD), a nonpsychoactive component of the marijuana plant, is a potent inhibitor of breast cancer cell proliferation, metastasis, and tumor growth.

In 2007, McAllister published a detailed account of how cannabidiol kills breast cancer cells and destroys malignant tumors by switching off expression of the ID-1 gene, a protein that appears to play a major role as a cancer cell conductor.

The ID-1 gene is active during human embryonic development, after which it turns off and stays off. But in breast cancer and several other types of metastatic cancer, the ID-1 gene becomes active again, causing malignant cells to invade and metastasize. “Dozens of aggressive cancers express this gene,” explains McAllister. He postulates that CBD, by virtue of its ability to silence ID-1 expression, could be a breakthrough anti-cancer medication.

“Cannabidiol offers hope of a non-toxic therapy that could treat aggressive forms of cancer without any of the painful side effects of chemotherapy,” says McAllister, who is seeking support to conduct clinical trials with the marijuana compound on breast cancer patients.

McAllister’s lab also is analyzing how CBD works in combination with first-line chemotherapy agents. His research shows that cannabidiol, a potent antitumoral compound in its own right, acts synergistically with various anti-cancer pharmaceuticals, enhancing their impact while cutting the toxic dosage necessary for maximum effect.

Investigators at St. George’s University in London observed a similar pattern with THC, which magnified the effectiveness of conventional antileukemia therapies in preclinical studies. THC and cannabidiol both induce apoptosis in leukemic cell lines.

At the annual summer conference of the International Cannabinoid Research Society, held this year in Freiburg, Germany, 300 scientists from around the world discussed their latest findings, which are pointing the way toward novel treatment strategies for cancer and other degenerative diseases. Italian investigators described CBD as “the most efficacious inducer of apoptosis” in prostate cancer. Ditto for cannabidiol and colon cancer, according to British researchers at Lancaster University.

Within the medical science community, the discovery that cannabinoids have anti-tumoral properties is increasingly recognized as a seminal advancement in cancer therapeutics.

Disclaimer : This website contains general information about cbd oil and the possible health benefits. The information is not advice and is not a substitute for advice from a healthcare professional. You must not rely on the information  as an alternative to medical advice from your doctor or other professional healthcare providers. FDA Disclosure:CBD products are not approved by the FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. While we publish and refer to currently available research on cannabidiol, terpenoids and other properties of hemp-derived cannabis oils, it is important to note: None of the products or information available on this website are intended to be a treatment protocol for any disease state. The information presented is for educational purposes only and should not be construed as medical advice or instruction.  The FDA would want us to remind you: You should always seek the advice of a physician before adding any supplements to your diet.

Leave a Reply

Your email address will not be published. Required fields are marked *